Gault EJ, Cole TJ, Casey S, et al. - The UK Turner syndrome (TS) study analyzed the impact on the final height of oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg) vs placebo from 9 years of age and delaying ethinylestradiol induction of puberty by 2 years from 12 (E12) to 14 (E14) years in growth hormone-treated girls with TS. The authors discovered that oxandrolone also raised the final height significantly by 4.1 cm compared with 4.6 cm previously. However, the E14 impact was no longer relevant at 2.7 cm compared with 3.8 cm previously.